Routine BRCA testing for ovarian cancer patients proves feasible in irish study

NCT ID NCT06274541

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether it is practical to routinely check ovarian cancer tumors for BRCA gene mutations in the clinic. Researchers enrolled 200 patients with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. They used blood and tumor samples to look for BRCA1/2 mutations, aiming to see if this approach works well for doctors and patients, and if it is cost-effective for the healthcare system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BRCA1/2 genetic testing

What this could lead to

If successful, this could make BRCA testing a standard part of ovarian cancer care, helping doctors choose better treatments and informing family members about their cancer risk.

What could go wrong

This was a small pilot study focused on feasibility, not on patient outcomes. The results may not apply to other healthcare systems or populations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube endometrioid adenocarcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma ovarian serous tumor primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bon Secours

    Cork, Munster, Ireland

  • Cork University Hospital

    Cork, Munster, Ireland

  • Mater Misericordiae University Hospital / Mater Private Hospital

    Dublin, Leinster, Ireland

  • St James's Hospital

    Dublin, Leinster, Ireland

  • University Hospital Limerick

    Limerick, Munster, Ireland